Skip to content

Stoke Therapeutics

US · STOK #2942 by market cap Listed 2019
24.29 -0.08 -0.33%
Live - 5344 symbols - heartbeat 470s ago · 2026-10-08 07:31
Pre-market 23.50 -3.25%
After-hours 24.29 0.00%
Market cap
1.57B
P/B
4.54
EPS
-0.12
Reader sentiment Are you bullish or bearish on STOK?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    TD Cowen Maintains Stoke Therapeutics(STOK.US) With Buy Rating
    Market Newswire · 2026/5/8
  • Rating change
    Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/2/11
  • Rating change
    CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $60
    Market Newswire · 2026/3/20
  • Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE)
    TipRanks · 2026/8/4
  • A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $40 to $60
    Market Newswire · 2026/8/5
  • Rating change
    BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $39
    Market Newswire · 2026/5/11
  • J.P. Morgan Upgrades Stoke Therapeutics(STOK.US) to Buy Rating, Raises Target Price to $40
    Market Newswire · 2026/8/21
  • Chardan Capital Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/8/4
  • Rating change
    H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2026/4/22
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK), Genelux Corp. (GNLX) and Celldex (CLDX)
    TipRanks · 2026/5/9
  • Rating change
    Guggenheim Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/5/8
  • Rating change
    Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/7/9
  • Rating change
    Jefferies Initiates Stoke Therapeutics(STOK.US) With Buy Rating, Announces Target Price $44
    Market Newswire · 2026/7/14
  • Rating change
    A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $38 to $60
    Market Newswire · 2026/5/9
  • Rating change
    Wedbush Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $38
    Market Newswire · 2026/3/18
  • Rating change
    Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $40
    Market Newswire · 2026/3/17
  • Rating change
    Guggenheim Initiates Stoke Therapeutics(STOK.US) With Buy Rating, Announces Target Price $60
    Market Newswire · 2026/2/5
  • CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $58
    Market Newswire · 2026/8/13
  • Rating change
    Wolfe Research Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $40
    Market Newswire · 2026/2/24
  • Rating change
    Wedbush Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $38
    Market Newswire · 2026/3/17

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 07:31:22 · For reference only, not investment advice and not tailored to your situation.